NEW YORK, March 07, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Omega Protein Corp. (“Omega” or the “Company”) (NYSE: OME) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Omega securities between August 3, 2016 and March 1, 2017, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/ome.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) the SEC is requesting information in connection with an investigation relating to Omega’s subsidiary’s compliance with its probation terms and Omega’s protection of whistleblower employees; (2) it is possible that the foregoing matter could result in a material adverse effect on Omega’s business, reputation, results of operation and financial condition; and (3) consequently, Defendants’ statements about Omega’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.
On March 1, 2017, post-market, Omega revealed that it had received a subpoena from the U.S. Securities and Exchange Commission seeking information about an investigation of Omega subsidiary’s compliance with its probation terms and Omega’s protection of whistleblower employees. Following this news, Omega stock dropped as much as $5.86 per share, or 22.32%, during intraday trading on March 2, 2017.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/ome or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Omega you have until May 2, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes
How Technology Is Reshaping Modern Business: From Operations to Customer Experience
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions
Want to cut your energy bills? Here’s how five experts are doing it
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 



